4//SEC Filing
QVT Associates GP LLC 4
Accession 0000899243-19-015062
CIK 0001740547other
Filed
May 28, 8:00 PM ET
Accepted
May 29, 6:05 PM ET
Size
12.8 KB
Accession
0000899243-19-015062
Insider Transaction Report
Form 4
QVT Associates GP LLC
10% Owner
Transactions
- Purchase
Common Shares, par value $0.000037453 per share
2019-05-24$7.70/sh+3,796$29,233→ 22,748,903 total(indirect: (see fn5)) - Purchase
Common Shares, par value $0.000037453 per share
2019-05-28$7.68/sh+3,807$29,245→ 22,752,710 total(indirect: (see fn5)) - Purchase
Common Shares, par value $0.000037453 per share
2019-05-29$7.55/sh+6,882$51,983→ 22,759,592 total(indirect: (see fn5))
QVT Financial Investment Cayman Ltd.
10% Owner
Transactions
- Purchase
Common Shares, par value $0.000037453 per share
2019-05-28$7.68/sh+3,807$29,245→ 22,752,710 total(indirect: (see fn5)) - Purchase
Common Shares, par value $0.000037453 per share
2019-05-29$7.55/sh+6,882$51,983→ 22,759,592 total(indirect: (see fn5)) - Purchase
Common Shares, par value $0.000037453 per share
2019-05-24$7.70/sh+3,796$29,233→ 22,748,903 total(indirect: (see fn5))
Footnotes (5)
- [F1]The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act.
- [F2]The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.66 to $7.74, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. ("Urovant"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.65 to $7.70, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.40 to $7.69, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4.
- [F5]QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,759,592 Common Shares held by Roivant because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein
Documents
Issuer
Urovant Sciences Ltd.
CIK 0001740547
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001290166
Filing Metadata
- Form type
- 4
- Filed
- May 28, 8:00 PM ET
- Accepted
- May 29, 6:05 PM ET
- Size
- 12.8 KB